Editor's Commentary: Additional Associate Editors,New Submission Category,and Meta-methodology

Tiihonen J Haukka J Taylor M A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. March 1, 2011, e-publication ahead of print, http://www.ncbi.nlm.nih.gov/pubmed/2136274 (accessed April 24, 2011).

Turner JR Satin LZ Callahan T Litwin J. The science of cardiac safety. Appl Clin Trials. 2010; 19(11, suppl):4–8, 14.

Kaul S. Presentation given at the DIA/FDA/CSRC-sponsored meeting, Cardiovascular Safety in Drug Development: State-of-the-Art Assessment, Washington DC, April 14, 2011.

Turner JR Durham TA . Integrated Cardiac Safety: Assessment Methodologies for Noncardiac Drugs in Discovery, Development, and Postmarketing Surveillance. Hoboken, NJ: John Wiley; 2009.

Kay R. Statistical Thinking for Non-statisticians in Drug Regulation. Chichester, UK: John Wiley; 2007.

Piantadosi S. Clinical Trials: A Methodologic Perspective, 2nd ed. Hoboken, NJ: Wiley-Interscience; 2005.

US Food and Drug Administration. Guidance for Industry. Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. December 2008.

European Medicines Agency. Draft Guideline. Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. January 2010.

Turner JR . New Drug Development: An Introduction to Clinical Trials, 2nd ed. New York: Springer; 2010.